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Our goal is to provide a perspective on current understanding of the origins of speciﬁcity in immune reactions, a topic that has intrigued
scientists for over a century. A fundamental property of adaptive immune responses is the ability to discriminate among an immense variety
of substances by means of antibodies (Abs) and Ab-like receptors on T lymphocytes [T-cell receptors (TCRs)], each able to bind a particular
chemical structure [the antigen (Ag)] and not, or only weakly, similar alternatives. Evidence has long existed, however, and has grown,
especially recently, that while exhibiting remarkable speciﬁcity, many individual Abs and TCRs can also bind a variety of very different
ligands. How canAg recognition by these receptors exercise the great speciﬁcity forwhich they are renowned and yet reactwith a variety of
different ligands (degeneracy)? We critically consider the mechanistic bases for this speciﬁcity/degeneracy enigma and also compare and
contrast Ag recognition by Abs and TCRs.
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H
umans and other vertebrates
depend on their innate and
adaptive immune systems for
protection against ubiquitous
microbial pathogens. The innate system
responds to evolutionarily conserved mo-
lecular patterns that are common among
pathogens. Because microbial patho-
gens evolve faster than higher organisms,
many pathogens have evolved strategies
for escaping innate immune responses.
If, however, a pathogen evades these
responses, signiﬁcant infection is still usu-
ally avoided by the adaptive immune sys-
tem’s ability to mount pathogen-speciﬁc
responses. These responses also result in
memory, which enables robust and quick
responses to the same pathogen when
encountered months, years, or even many
decades later (1).
The speciﬁcity of protein–ligand inter-
actions is evident throughout biological sys-
tems (e.g., in the evolution of enzymes to
bind substrates). What is remarkable about
the speciﬁcity exhibitedby immune reactions
is that it arises during the individual organ-
ism’s lifetime and can be directed to ligands
that are not encountered in its ancestral
history and may not even exist in nature.
Because it is pathogen-speciﬁc, a funda-
mental property of adaptive immunity is
the ability to react against the agent that
triggers a response [an antigen (Ag)] and
not to multitudes of others. Two types of
cells, T lymphocytes (T cells) and B lym-
phocytes (B cells), and the cell surface
receptors they express, the α/β T-cell re-
ceptor (TCR) on T cells and membrane-
bound Abs on B cells, mediate these
discriminating responses. The ability to
distinguish among similar ligands is not
limited to pathogens. It extends to a vast
number of different organic structures,
and the speciﬁcity of Ab reactions with
Ags is currently exploited to measure
hundreds of different analytes and to treat
various noninfectious diseases (e.g., can-
cer, autoimmune disorders, asthma). In
addition to binding one Ag and a few
similar structures, however, many TCRs
and Abs have been found to bind a variety
of distinctly different ones, engaging in
what is variously referred to as degenerate,
multispeciﬁc, or polyspeciﬁc binding.
Here, we consider this paradoxical be-
havior by examining how the concept of
speciﬁcity, especially its mechanistic basis,
has evolved over the past century.
Ab Speciﬁcity
The speciﬁcity of immune reactions was
initially demonstrated with reactions of
serum from Ag-injected animals with Ags
in the form of pathogenic bacteria and
their toxic culture ﬁltrates and soon
thereafter with a great variety of other Ags,
including plant proteins, red blood cells,
milk, and ovalbumin, for example. Similar
speciﬁcity was evident around the same
time in studies of enzyme-substrate reac-
tions. From work with invertase and simple
substrates, such as α- and β-methyl glu-
cose, Emil Fischer was led to propose that
“. . .to be able to act chemically on one
another, an enzyme and its substrate must
ﬁt together like a lock and key.” Despite
marked differences between the simple
substrates recognized by some enzymes
and the complex Ags that elicited immune
reactions, this metaphor became ﬁrmly
rooted in the thinking of immunologists.
Landsteiner (2) subsequently coupled
simple aminobenzene derivatives co-
valently to proteins, and by raising antisera
to protein conjugates of these small mol-
ecules (haptens), he opened the way for
speciﬁcity of immune reactions to be ex-
amined with molecules as simple as those
used to probe enzyme-substrate reactions.
Serum from animals injected with these
conjugates (antihapten antisera) distin-
guished sharply among closely related
molecules, for example, between diaster-
eoisomers (D- and L-tartaric acid). Cross-
reactions were commonly observed, but
obvious structural similarities among
cross-reacting haptens only powerfully
served to reinforce the idea that the
speciﬁcity of antisera was attributable to
a lock-and-key ﬁt of an Ab to its Ag.
A mechanistic basis for this metaphor
was clearly set out by Pauling in Land-
steiner’s classic monograph, wherein the
speciﬁcity of Abs for Ags was attributed to
their possessing “such mutually comple-
mentary conﬁgurations that the surface
of one conformed closely to the surface
of the other. . . (allowing many). . . weak
forces, themselves not speciﬁc. . .” to pro-
vide “a total energy of interaction. . . that
caused. . . the two molecules to attract
one another very strongly” (2). This was in
accord with the then prevailing idea that
Ab molecules were all structurally the
same except for the shape of their binding
sites. The residues comprising the binding
site were believed to be folded into a
conﬁguration that was complementary in
shape to the Ag, which was postulated to
act as a template (3, 4). This view was
so strongly held that it led to more than
one report that when proteins from the
gamma globulin fraction of serum (the
fraction wherein most Ab activity is found)
were denatured and allowed to refold in
the presence of a chosen Ag, the ability
to react speciﬁcally with that Ag was
acquired (5).
It was later shown, however, that puriﬁed
Abs to anAg (call it X) could be completely
denatured, including reduction of all Ab
disulﬁde bonds, and would regain anti-X
speciﬁcity when allowed to refold in the
absence of X (6, 7). This meant that an
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Ab’s speciﬁcity is dictated by its amino
acid sequence, and is thus determined
before encountering the Ag. These ﬁnd-
ings were fully in accord with the radical
proposal made a few years earlier that
Ab-producing cells differ in the Ab they
make and that an Ag acts by selectively
stimulating only those cells that make
a matching Ab (8, 9). This cell or clonal
selection hypothesis amounted to the view
that before encountering Ag, the Ab
molecules made by a B cell have a partic-
ular amino acid sequence and, as a conse-
quence, a singular binding site that ﬁts
one Ag and perhaps a few similar ones.
Efforts to compare the amino acid se-
quences of Abs that react with different
Ags were frustrated, however, by Ab het-
erogeneity. Thus, when isolated from an-
tisera and highly puriﬁed to the point
where they were completely reactive with
the corresponding Ag, puriﬁed Abs were
still almost invariably heterogeneous in
isoelectric points, N-terminal amino
acids, and other properties (10). A way
around this roadblock was subsequently
provided with proteins produced by
myeloma tumors.
Myeloma Proteins
Each myeloma tumor, a clone of a partic-
ular cancerous plasma cell, typically
secretes immense amounts of a protein
(a myeloma protein) that is homogeneous
but antigenically similar to conventional
Abs. For instance, rabbit Abs raised against
puriﬁed human Abs react with human
myeloma proteins (and vice versa). Be-
cause of their homogeneity, myeloma
proteins (of humans and mice) were key
players in validating the four-chain struc-
ture of Ab molecules (11), and they
(i) helped to establish that Abs are het-
erodimers, formed of heavy (H) and
light (L) chains (12, 13);
(ii) identiﬁed various classes of H chains
and types of L chains (14);
(iii) revealed that L chains of the same
type but from different patients
(i.e., different tumor clones) had
the same amino acid sequence in
the C-terminal domain but a tumor
(clone)-distinctive sequence in the
N-terminal domain (15); this, in
turn, revealed the pattern of variable
(V) and constant (C) domains, which
proved to be a universal property of
all Ab L and H chains as well as the
subunits that make up the TCR;
(iv) made possible the discovery that
gene segment rearrangements dur-
ing B-cell development formed the
genes that encode Abs (16);
(v) provided the ﬁrst evidence for so-
matic mutations in V domains (17).
That a small proteolytic fragment con-
sisting of just an Ab’s H- and L-chain V
domains (the Fv fragment) harbors the
complete binding site for Ag and the anti-
genically distinctive element that marks the
individuality (“idiotype”) of each Ab was
alsodiscoveredwith amyelomaprotein (18).
Because myeloma proteins and con-
ventional Abs are indistinguishable struc-
turally, the probability that any chosen Ag
would bind to any particular myeloma
protein was expected from the clonal se-
lection hypothesis to be so small that many
thousands of these proteins would have to
be examined to ﬁnd one that bound the
chosen Ag. Instead, using a distinctive
spectral shift of the 2,4-dinitrophenyl
(DNP) group when bound to anti-DNP
Abs from diverse animal species as a
readout, far fewer than 50 human myeloma
proteins and a like number of mouse
myeloma proteins had to be screened
before ﬁnding those that bound e-DNP-
lysine (19, 20) with an intrinsic afﬁnity
commonly found as an average value for
polyclonal antihapten Abs (equilibrium
dissociation constant, KD 1–10 μM). By
screening with precipitation reactions,
other myeloma proteins were readily
found to bind other Ags and haptens
(dextrans, levans, glycoproteins, and
phosphorylcholine) (21, 22). When one
of the anti-DNP myeloma proteins
(MOPC-315) was tested systematically
with about 57 common laboratory chem-
icals, it bound vitamin K3 (menadione,
a naphthaquinone that vaguely mimics the
2,4-DNP group) and also several entirely
dissimilar small molecules, notably tetra-
hydrofolate, ﬂavin mononucleotide, and
caffeine (23). This and similar reports of
degenerate binding (24, 25) may not have
elicited more attention at the time, be-
cause despite all the evidence that mye-
loma proteins are structurally the same as
Abs, they were viewed by many as “para-
proteins,” or abnormal products of ab-
normal (cancer) cells (26).
Monoclonal Antibodies (mAbs)
Once it became possible to produce mAbs
following Köhler and Milstein’s landmark
publication (27), a considerable number of
them were also found to bind diverse li-
gands. For example, an anti-DNP mAb
(SPE7) raised against a typical DNP-
protein conjugate (Eshhar et al. 1980, in
ref. 28) was found to bind, in addition to
DNP-amino acids, some heterocyclic
molecules with substantial afﬁnities (e.g.,
alizarin red, furazolidone, with a KD in
nanomolar to micromolar range) and also
12 different peptides displayed as loops in
a protein (thioredoxin) (28).
Another mAb (CB4-1) made in response
to recombinant protein p24 from the HIV-
1 virus, bound 5 peptides unrelated to
p24 with afﬁnities like that for the p24
immunogen and also several unrelated
microbial proteins (29). Likewise, a mAb
to phenyl arsonate and another mAb to
nitrophenyl bound 20–25 different pep-
tides displayed in a phage library (30).
A mAb (7G12) raised against a porphyrin
bound an unrelated polyether (31).
Moreover, two mAbs (2F5 and 4E10)
from HIV-infected individuals reacted
with a viral protein (gp41) and also bound
cardiolipin and other phospholipids (32,
33). Yet another mAb (IgG1b12) from
an HIV-infected person, in addition to
binding the gp120 protein of the virus,
reacted with dsDNA, histones, and “cen-
tromere B” (33). Most notably, about
20% of the mAbs derived from 141 IgG-
expressing memory B cells in normal hu-
man subjects were found to be multi-
reactive when tested with a limited set of
diverse ligands (dsDNA, ssDNA, LPS, and
insulin) (34). Despite binding ligands as
different as, for example, a protein and
small aromatic haptens, multireactive
mAbs can distinguish between small
structural variants of the disparate ligands
they recognize; hence, their binding de-
generacy is also called multireactivity,
multispeciﬁcity, or polyspeciﬁcity (35).
An important implication of multi-
speciﬁcity is that a B cell that responds to
a particular pathogen or Ag might also
respond to a variety of other Ags, implying
that the number of B cells does not limit
the number of different Ags that can elicit
Ab responses.
Mechanistic Basis for the Ab
Speciﬁcity/Degeneracy Enigma
Insight into how an Ab can engage in both
speciﬁc and degenerate Ag recognition
emerged initially from studies of the
“preequilibrium” kinetics of Ab-Ag bind-
ing (on a millisecond time scale), com-
plemented by information obtained from
X-ray crystal structures. Carried out ini-
tially with a myeloma protein that recog-
nized a DNP amino acid (36) and then
with mAbs to phenyloxazolone (37), as-
sociation rates could not be ﬁt to a single
exponential function in the myeloma pro-
tein and in 10–20% of the antihapten
mAbs. Multiphasic kinetics with up to
three stages were observed (28). The data
were ﬁt to a number of models, the most
general of which is shown in Fig. 1. An
Ab can exist in a number of different free
conformations in equilibrium, with two
possible routes to Ag binding. In one
(Fig. 1 Upper), an Ag binds to one of
the conformers to form an encounter com-
plex that, if sufﬁciently persistent (as in
kinetic proofreading) (38), would allow an
induced ﬁt mechanism to ensue and result
in a further change in conformation,
leading to strong binding. A variant of
this scheme (not shown) is that an Ag can
bind to various Ab conformers before
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induced ﬁt-mediated stronger binding. In
the second scheme (Fig. 1 Lower), an
available Ab conformer can bind a variety
of different Ags to different side chains in
the Ab’s combining site (39, 40); these
ﬁndings suggest that although each ligand
made different contacts, a few key inter-
actions with Ab combining site residues
locked the Ab into a conformation that
allowed stable binding with the disparate
ligands. Although this mechanism seems
to differ from conformational isomerism
as the basis for multispeciﬁcity, it may be
that for a given Ab, multispeciﬁcity can
arise from either of the schemes shown in
Fig. 1, depending on the Ag and the ki-
netic constants for the different paths.
The idea emerging from kinetic studies
that interconvertible Ab conformations
differ in ligand-binding activity was in ac-
cord with X-ray crystal structures that
showed conformation differences, which
were pronounced in some cases, between
ligand-bound and free Abs (41–43). A
comprehensive kinetic and X-ray crys-
tallographic analysis of the Fv fragment
of the anti-DNP Ab referred to above
(SPE7) is especially illuminating (28). This
Ab could adopt several conformations in
a dynamic equilibrium and could bind
various small aromatic haptens in tran-
sient encounter complexes, allowing the
Ab in sufﬁciently long-lived ones to adopt
still other conﬁgurations with enhanced
combining site complementarity to the
bound ligand. This Ab’s conformational
plasticity was also evident from the dif-
ferent shapes of its combining site when
occupied by different ligands—a deep
pocket when the bound ligand was a small
aromatic hapten and a shallow ﬂat surface
when it was a protein.
Multispeciﬁcty vs. Monospeciﬁcity
How can Ab multireactivity be reconciled
with the apparent monospeciﬁcity of the
many mAbs that are used reliably in ana-
lytical assays, and even as therapeutic
agents? Some possible answers stem
from the changes undergone over time as
naive B cells respond to an Ag (Fig. 2).
The binding of an Ag to membrane-bound
Ab on a naive B cell stimulates the cell
to divide. A cytidine deaminase activated
in proliferating B cells causes mutations
throughout V domains of both H and L
chains (44). (It also causes “class switch-
ing” of the V domain from the Ab’s H
chain (μ in naive B cells) to the C domain
of one of the lower molecular weight H
chains (γ, α, or ε) expressed in more ma-
ture B cells. The mutated Abs vary in
afﬁnity for the Ag, and their average
monovalent (intrinsic) afﬁnity increases
over time, with the rate of increase de-
pending on the amount of Ag exposure:
Small amounts lead to rapid increases in
afﬁnity, and large amounts greatly reduce
the rate of increase (45). It thus appears
that decreasing levels of Ag act selectively
to stimulate B cells that produce higher
afﬁnity Ab. After Ag disappears, some
B cells survive and endure indeﬁnitely as
“memory cells.” When restimulated by
Ag even years later, they promptly pro-
duce the high-afﬁnity Abs they were
making before becoming quiescent (46).
H-chain class switching and hyper-
mutation take place within germinal cen-
ters of lymph nodes (47, 48). Hence, B
cells that have undergone this process and
then dispersed throughout the body are
called “postgerminal center” memory
B cells, and the Abs they produce are
“afﬁnity-matured.”
Against this background (Fig. 2), it has
been proposed that the Abs made in the
initial (primary) response to an Ag are
ﬂexible and multireactive, whereas those
made later have combining sites that are
less cross-reactive, more rigid, and better
adapted conformationally to the Ag,
thereby binding it with higher afﬁnity (31,
49–51). Some evidence supports this pos-
sibility; for instance: (i) crystal structure
differences between some afﬁnity-matured
Abs and their presumed precursor early
response Abs (49), (ii) molecular dynam-
ics simulations that show decreasing con-
formational ﬂexibility of an Ab that has
been subjected to successive rounds of
mutation and selection for higher afﬁnity
variants by directed evolution in vitro
(52), (iii) more unfavorable entropy
changes associated with ligand binding
by the IgM Abs made initially to an Ag
than with the afﬁnity-matured IgG Abs
produced later (30, 50), and (iv) consid-
erable conformational ﬂexibility and mul-
tireactivity of a germline-encoded Ab (39).
In apparent conﬂict with the foregoing,
most of the mAbs demonstrated to be
multireactive are afﬁnity-matured (i.e.,
they have V domain mutations and
switched H chains). The contradictory
ﬁndings are inconclusive, however, because
the increase in average afﬁnity of the
Abs produced over time is accompanied
by increasing heterogeneity of afﬁnity
values (45), a likely consequence of
the stochastic nature of the cytidine
deaminase-driven hypermutation in V
domains (44). Hence, mAbs derived
from a few B cells plucked at random from
heterogeneous pools of B cells with di-
versiﬁed Ab combining sites might be
highly speciﬁc or highly multireactive.
Ab *  + Ag 1 
s low 
  (Ab *  - Ag 1 )               (Ab * ′  – Ag 1 ) induced  fi t 
Ab  + Ag 2 
f ast 
  (Ab – Ag 2 )  
Ab **   + Ag 3 
f ast 
  (Ab **  – Ag 3 )  
Ab ***  + Ag 4 
s low 
  (Ab ***  - Ag 4 )              (Ab ***  – Ag 4 ) 
Ab *   + Ag 1                (Ab ***  – Ag 1 ) 
Ab  + Ag 2               (Ab ***  – Ag 2 )  
Ab **     + Ag 3               (Ab ***  – Ag 3 ) 
Fig. 1. General scheme for Ag recognition by Ab.
(Upper) Various free Ab conformers bind different
Ags (e.g., Ag1, Ag2), but only one complex (or
a few) persists long enough for further confor-
mational changes to occur (induced ﬁt) and yields
strong Ab-Ag binding. (Lower) Conformers can
bind various Ags to different subsites in the con-
formers’ combining site, thereby locking the Ab
into a single conformation that binds different
Ags. *, **, and *** represent different Ab con-
formations.
X,X'
X,X',Y
IgM
X (X)
I
Selection / Activation
II
Proliferation / Mutation
III
Selection of higher 
affinity mutants
IV
Restimulation of 
memory cells
Fig. 2. Maturation of Ag-stimulated B cells. Ag (X)-stimulated naive B cells (I) proliferate and acquire
mutations in Ab V domains (II), yielding progeny cells that express cell-surface Abs that differ in their
afﬁnity for the Ag (lower afﬁnity, open symbols; higher afﬁnity, closed symbols) and in their ability to
bind just a few ligands (V domain, rectangles) or a variety of different ligands (V domains, irregular
circles). Decreasing Ag levels selectively stimulate the higher afﬁnity Ab-producing B cells (III), some of
which become memory cells that can be restimulated later (IV) by an Ag that is the same as the original
(X), a variant of it (X′), or structurally entirely different (Y) to produce higher afﬁnity relatively speciﬁc
(Upper) or multispeciﬁc (Lower) Abs.
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An entirely different explanation for
degenerate Ag recognition by some
afﬁnity-matured IgG Abs has emerged
from studies by Nussenzweig and col-
leagues (34, 53, 54) of hundreds of mAbs
derived from single human B cells. About
5% of mAbs from mature naive B cells
bind multiple ligands (e.g., dsDNA,
ssDNA, insulin, LPS) (54). The frequency
of multireactivity with these ligands is in-
creased to about 20% of mAbs from
IgG memory B cells (34). In some HIV-
infected individuals, it is increased even
more, to about 75% of the B cells that
make mAbs that bind gp140, a prominent
antigenic glycoprotein spike on the HIV-1
virus (53). Many of these mAbs, like the
multireactive 2F5 and 4E10 mAbs from
other HIV-infected individuals, also bind
cardiolipin, a phospholipid in many cell
membranes (32, 33). The remarkably
high frequency of these multireactive Abs,
which have switched H chains and mu-
tated V domains, suggests that they are
selected by the HIV-1 virus, particularly
during afﬁnity maturation.
Why might B cells that make multi-
reactive IgG Abs be selected? The two
ligand-binding sites per IgG Ab molecule
are structurally and functionally identical.
They can characteristically bind simulta-
neously to closely spaced copies of the
same epitope, as on common microbial
Ags, like the hemagglutinin spikes on
inﬂuenza virions or capsular poly-
saccharides of pneumococci. The afﬁnity
enhancement conferred by this form of
bivalent binding may not be possible,
however, for the multireactive anti-gp140
Abs, because the very few gp140 spikes per
HIV-1 virion are likely too far apart (>15
nm) (53, 55). If, however, the binding
sites of these Abs are conformationally
ﬂexible, one site could bind with high af-
ﬁnity to gp140 and the second site of the
same Ab molecule could bind with low
afﬁnity to a different epitope on the same
virion. The cooperativity inherent in
this bivalent interaction could enhance an
Ab molecule’s binding to the virion (53)
even if one of the ligands is bound very
weakly. This asymmetrical binding or
“heteroligation” requires multireactive
combining sites. It differs distinctly from
other forms of heteroligation, such as that
displayed by genetically engineered bispe-
ciﬁc Abs [formed by joining two half
molecules (H-L heterodimers) from
different mAbs].
Like some mAbs from HIV-1–infected
individuals, serum Abs that bind car-
diolipin and other self-Ags have long been
known to occur in some persistent in-
fections in humans (e.g., Epstein–Barr vi-
rus, hepatitis B virus, syphilis treponeme)
and in mice (e.g., vaccinia virus) (56).
Indeed, myeloma proteins, where evidence
for Ab multireactivity surfaced about 40 y
ago, have recently been found to have
multiple V region mutations, and the my-
eloma tumor cells that produce them have
been found to arise from postgerminal
center memory B cells (57, 58). It is thus
possible that highly multireactive mAbs,
such as SPE-7, CB4-1, and others (see
above), are products of memory B cells
that remain from previous responses to
certain pathogens and are later cross-
stimulated by different Ags (59, 60) (Fig.
2, represented by Y).
Overall, it appears that afﬁnity-matured
Abs may be relatively rigid and highly
speciﬁc or conformationally ﬂexible and
multireactive, depending on the nature
of the selecting Ag, especially during af-
ﬁnity maturation (Fig. 2).
Speciﬁcity Measured as Risk
Speciﬁcity is usually thought of simply as
the ability “to bind one unique chemical
structure more strongly than a number
of similar alternatives.” That Abs may
differ greatly in extent of speciﬁcity, and
possibly even systematically over the
course of immune responses, points to
a need to measure degrees of speciﬁcity. If
speciﬁcity is deﬁned as the risk for en-
gaging in confounding reactions with
structurally different ligands, a useful
metric could be the frequency with which
a mAb reacts with diverse ligands in
standardized libraries of small molecules,
peptides, or immobilized proteins. Such
standard measures should clarify the fre-
quency of multireactivity in Abs generated
in response to various pathogens and
vaccines or produced for analytical or
therapeutic purposes.
T-Cell Speciﬁcity
Background. The Ag-recognizing receptors
on T cells (TCRs) of the adaptive immune
system are αβ-heterodimers that structur-
ally resemble the Ag-binding (Fab) frag-
ment of Abs. Like Abs, TCRs are encoded
by genes formed by gene segment re-
arrangements, and most T cells express
a singular TCR (61–66). However, TCRs
and Abs recognize entirely different Ags.
Populations of Abs (and their precursors
on surfaces of B cells) can recognize vir-
tually any conceivable organic molecule in
solution or on cell surfaces. Abs do not,
however, penetrate into cells; hence, they
protect against extracellular pathogens
(e.g., bacteria or virions that have not yet
infected host cells). T cells do not respond
to extracellular pathogens; however, they
recognize intracellular proteins, and can
thus destroy virus-infected and cancerous
cells that produce aberrant proteins.
Intracellular proteins are cleaved into
peptides by proteasomes or by peptidases
in endocytic vesicles. Virtually all cells also
express proteins encoded by the MHC
genes. These proteins have a groove, where
a peptide derived from intracellular pro-
teins can potentially bind via noncovalent
interactions with 1:1 stoichiometry (67,
68). Generally, two preferred amino acid
residues, properly spaced, are needed for
a peptide to bind (69). Termed pMHC,
these peptide MHCs (pMHCs) are the
Ags that T cells recognize. (The peptides
of recognized pMHCs are also called
epitopes.) Recognition implies sufﬁciently
strong TCR binding to a pMHC to trigger
a T-cell response.
A structural basis for the puzzling pro-
pensity of TCRs to “see” MHC proteins
is emerging from detailed comparisons of
TCR-pMHC crystal structures (70–74).
These show that in complementarity de-
termining regions of the TCR (CDR1 and
CDR2), there are some conserved resi-
dues that interact with various conserved
combinations of MHC residues in the he-
lices that ﬂank the epitope-binding groove.
This evidence for coevolution of TCR and
MHC genes is in accord with the ﬁnding
that thymocytes that have never seen
MHC (from MHC KO mice) recognize
various pMHCs with the same frequencies
as thymocytes that mature in the abundant
presence of pMHCs (75).
The peptides that bind to one class of
MHC proteins (MHC-I) are usually short
(8–10 mers) and recognized by T cells
that express the CD8 coreceptor (CD8+
T cells or cytotoxic T lymphocytes). Larger
peptides (10–20 mers) bind to another
MHC class (MHC-II) and are recognized
by T cells that express the CD4 co-
receptor (CD4+ T cells). We shall not
distinguish here between pMHC-I and
pMHC-II because their interactions with
TCRs (on CD8 and CD4 T cells, re-
spectively) are similar, although the re-
sponses triggered by pMHC recognition
are different. CD8+ cells kill cells that
display the recognized pMHC; CD4+
cells can also kill cells but do so more
slowly, and their main function is to se-
crete cytokines that regulate various
immune responses, including those that
help B cells to mature.
There are few major MHC genes in the
genome (six in humans), but there are
thousands of allelic variants of them.
Unrelated individuals in, for example,
human populations thus almost invariably
express some dissimilar MHC proteins.
Although each individual expresses only
a few MHC alleles, the number of pMHCs
that can form is immense because each
MHC protein can bind tens of thousands
of different peptides.
TCR-pMHC reactions are usually highly
speciﬁc. For example, TCRs can discrimi-
nate sharply between peptides whose
sequences differ by only a single homolo-
gous amino acid replacement (e.g., F/Y,
L/I). The responses can also be degenerate,
as when a T cell responds robustly to
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pMHCs whose peptides have entirely
different sequences.
Degeneracy is also evident in the ability
of T cells to respond to pMHCs whose
MHCs are foreign, as from other individ-
uals of the same species (allogeneic MHC)
or even other species (mouse T cells to
human pMHC, and vice versa). From the
high frequency (1–10%) of T cells that can
recognize particular allogeneic MHCs
and the great number of variant MHC
alleles, it is apparent that most T cells, and
perhaps every T cell, can respond to one
or more allogeneic pMHCs (76–80) in
addition to responding to a self (synge-
neic)-MHC carrying different peptide
epitopes. The intensity of alloreactions
underlies the almost invariable rejection
of MHC-disparate organ transplants,
unless the recipient is immunosuppressed.
Alloreactivity implies that T cells can
recognize very diverse peptides, because
the repertoire of peptides that bind
to different MHCs usually differs consid-
erably.
The speciﬁcity/degeneracy enigma that
characterizes many TCR-pMHC reactions
is illustrated by the following T-cell clones.
One (2C) arose in a b mouse (81), another
(BM3.3) arose in a k mouse (82), and
another (LC13) arose in a B8+B44− hu-
man (83). Examples of different pMHCs
recognized by these clones are shown
(allogeneic complexes are underlined;
peptides are in boldface; and Ld, Kb, B8,
and B4405 represent particular class I
MHC proteins):
Clone2C(mouse) recognizesQLSPFPFDL/
Ld and SIYRYYGL/Kb
BM3.3 (mouse) recognizes INFDFNTI/Kb
and RGYVQGL/Kb
LC13 (human) recognizes FLRGRAYGL/
B8 and EEYLQAFTY/B4405
In addition to recognizing such different
ligands, the TCRs of these and similar
clones react speciﬁcally, discriminating
sharply between variants of the bound
peptides (82, 84–87) and between MHC
proteins that may differ by only two or
three residues.
Mechanistic Bases for the T-Cell Speciﬁcity/
Degeneracy Enigma. Molecular mimicry. Mo-
lecular mimicry postulates that different
pMHCs must have structural elements in
common if they are recognized by the same
TCR. The idea grew from efforts to ac-
count for the role of Abs and T cells that
recognize both autologous (self) and mi-
crobial Ags in autoimmune diseases (88).
When applied to TCRs that react with
different peptides bound to the same
MHC, sequence similarity between cross-
reacting peptides is clear in some cases
(89) but barely apparent in others [e.g.,
limited to a single homologous residue
shown in X-ray crystal structures to be
solvent-exposed or to make contact with
the TCR (90, 91)].
Predicting cross-reactions from peptide
sequence similarities alone can also be
confounded by changes in epitope conﬁg-
uration that occur when some pMHCs are
engaged by TCRs (92, 93). X-ray crystal
structures showed a surprising similarity
in the conﬁgurations of two sequence-
dissimilar peptides when the respective
pMHCs (one syngeneic and the other al-
logeneic) were engaged by a particular
TCR (LC13) (90). The authors thus attri-
bute this striking example of degenerate
recognition to an “induced ﬁt mechanism
of molecular mimicry.” It seems, however,
that the molecular mimicry in this case is
a consequence of the cross-recognition
rather then its cause (94). We comment
later on how this observation may ﬁt
within a general proposed model.
We conclude that although molecular
mimicry can provide useful insights into the
pathogenesis of disease, its application
to the speciﬁcity/degeneracy issue is
fraught with uncertainty.
TCR ﬂexibility. More than 20 X-ray crystal
structures have now been solved for
TCRs in free and pMHC-bound forms. In
these structures (95–97), the TCR consis-
tently assumes a diagonal position, with
varying angles over the pMHC, allowing
TCR variable loops formed by CDRs to
contact distinctive regions of pMHCs.
CDR1 and CDR2 mostly contact MHC
helices that ﬂank the epitope-binding
groove. Usually, CDR3 makes the most
contacts with the central amino acids of
the epitope (98).
The generally favored interpretation of
the crystallographic and thermodynamic
ﬁndings is that CDR loop ﬂexibility enables
a TCR, when bound to a pMHC, to adopt
a conformation that enhances comple-
mentarity to different epitopes (induced
ﬁt). With some TCRs, the CDR3 loops
indeed assume different conformations
when engaged with different pMHCs
(e.g., 91, 99, 100). Some kinetic studies
are consistent with an induced ﬁt process
(101, 102), but others question it (95).
TCR-pMHC interface complementarity
may also be affected by changes in epitope
conﬁguration (90, 92, 94, 99). There is
generally less complementarity at the
TCR-pMHC interface than between Ag-
Ab interfaces, in keeping with the sub-
stantially lower afﬁnities of TCR-pMHC
than Ag interactions with afﬁnity-matured
Abs (although not lower than Ag binding
to preafﬁnity-matured Abs).
Both favorable and unfavorable entropy
changes occur with TCR-pMHC binding,
but these changes are difﬁcult to parse
into contributions from conformation
changes or reordering of water molecules.
CDR loops of TCRs do not undergo
large-scale reorganization or folding on
ligand binding, Most changes amount to
relatively modest rigid shifts (e.g., hinge-
bending) (95), consistent with the obser-
vation that only about 10% of speciﬁc heat
changes incurred on binding can be at-
tributed to change in conformation.
Moreover, in some TCRs, there is essen-
tially no change in CDRs on binding
markedly different pMHCs (see 2C TCR
above) (103). Thus, TCR ﬂexibility does
not generally provide a sufﬁcient basis for
degeneracy in TCR–pMHC interactions;
a highly ﬂexible TCR would also be unable
to exhibit speciﬁcity.
Bar code model. Another mechanistic view
of the speciﬁcity/degeneracy enigma stems
from considerations of the statistical
properties of the TCR repertoire rather
than analyses of the detailed interactions
of particular TCR-pMHC pairs. Because
the TCR diversity attributable to gene
rearrangements is enormous and their
selection during development in the thy-
mus varies among individuals, such a sta-
tistical view may provide general insights
applicable to many TCRs (104).
For a developing T cell (thymocyte) to
mature, it must pass two tests (105). First,
its TCR must bind to at least one of the
several endogenous (self) MHCs displayed
with various self-peptides on thymic Ag-
presenting cells with an afﬁnity that
exceeds a threshold. A T cell that passes
this test (“positive selection”) is able to
respond to viral and other foreign peptides
associated with the MHC type that
mediated positive selection (resulting in
“MHC restriction of Ag recognition”).
Second, a thymocyte must also not be
negatively selected; that is, if its TCR
binds to any of the self-pMHCs it en-
counters in the thymus with an afﬁnity
that exceeds another threshold above the
positive selection threshold, it is likely to
be eliminated. This limits the number
of T cells potentially able to trigger
autoimmune disease.
Huseby et al. (106, 107) reported that
the speciﬁcity of T cells differs greatly,
depending on the diversity of pMHCs that
they encountered in the thymus. T cells
that matured in mice, in which many self-
pMHCs are expressed in the thymus, are
usually highly speciﬁc; that is, their rec-
ognition of a particular pMHC is abro-
gated by most point mutants of that
peptide. In contrast, T cells that matured
in mice engineered to express only one
type of pMHC react more degenerately
when assayed in this manner.
Using computational methods rooted in
statistical physics, independent of the
choice of parameters used to estimate
TCR-pMHC binding free energies, it was
predicted that T cells whose TCR peptide
contact residues are composed of amino
acids that interact strongly with other
amino acids (e.g., charged, strongly
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hydrophobic, with very ﬂexible side chains)
aremore likely to be eliminated by negative
selection in a thymus that expresses a great
diversity of self-pMHCs (104). Analysis
of available TCR-pMHC crystal structures
showed that peptide-contact residues of
TCRs are indeed enriched with those
amino acids that are determined by bio-
informatic studies to interact weakly with
other amino acids (108). These results are
consistent with ﬁndings that T cells se-
lected in a mouse that expresses a single
self-pMHC have TCR-pMHC interfaces
that are more highly hydrophobic than
those of TCRs that develop in WT mice
(70). The paucity of amino acids with
ﬂexible side chains in the peptide contact
residues of TCRs in mature T cells re-
inforces the ﬁndings that TCR CDR3
loops are not dynamically disordered and
that there is no large-scale reorganization
of these loops on ligand binding.
These ﬁndings suggest that because the
peptide contact residues of mature TCRs
are statistically likely enriched in weakly
interacting amino acids, peptide recogni-
tion is mediated by multiple relatively weak
interactions, because only then can their
summation achieve a sufﬁcient level to
elicit a T-cell response. In contrast, TCRs
derived from mice with only one type of
self-pMHC in the thymus allow TCRs with
strongly interacting peptide contact resi-
dues to emerge into the periphery, making
it likely that epitopes can be recognized
via one or two dominant strong inter-
actions mediated by these residues. These
results are consistent with calorimetric
experiments with TCRs derived from
mice that present one or many types of
peptides in the thymus (106, 107).
For a typical T cell in a normal reper-
toire, the need for multiplicity of TCR-
peptide interactions may account for
speciﬁcity, because weakening even one
interaction may make a signiﬁcant per-
centage change to the binding free energy,
and this could abrogate recognition be-
cause strong nonlinearities in the T-cell
signaling networkmake T cells respond in a
digital (either “on” or “off”) fashion across
a sharply deﬁned interaction strength
threshold (109, 110). In contrast, periph-
eral T cells selected against one or few
self-pMHCs are likely to be cross-reactive,
because only mutations at the sites that
dominate the TCR-pMHC binding free
energy are likely to abrogate recognition.
Such T cells are also likely to bind MHCs
with relatively high afﬁnity, which would
enhance cross-reactivity.
A TCR enriched in weakly interacting
amino acids in its peptide contact residues
will likely recognize epitopes that are
enriched in amino acids that are among
their stronger binding complements to
generate a sufﬁcient number of moderate
interactions (e.g., Y,F,L,I,V in peptides
recognized by TCR 2C, BM3.3, LC13,
above). Thus, a point mutation to the epi-
tope is likely to weaken the interaction,
leading to abrogation of recognition for
reasons noted above (i.e., speciﬁcity).
Permuting/substituting the amino acids in
such a recognized epitope with homolo-
gous ones can still lead to a sufﬁcient
number of moderate interactions to elicit
a T-cell response (degeneracy), however.
Rather than emphasizing lock-and-key
complementarity, a more apt metaphor for
this model of TCR recognition of pMHC
complexes is that of a bar code (Fig. 3):
The TCR (bar code reader) scans the
peptide (bar code) for a sufﬁcient number
of moderately thick lines.
Even inWTmice or normal humans with
many thymic self-pMHCs, the pool of
mature T cells can include highly de-
generate T cells. This may be attributable
to heterogeneous microenvironments in
the thymus (111, 112), as a result of which
different thymocytes will encounter dif-
ferent numbers of self-pMHCs. Further-
more, because of the stochastic character
of T-cell signaling, not every strong in-
teraction will result in negative selection.
The statistical nature of the arguments in
the bar code model makes it relevant for
a typical T cell but not for every one.
Such statistical considerations may be
potentially important in human immune
responses to the HIV-1 virus. The HLA-
B57 human MHC molecule tends to bind
a smaller diversity of self-peptides; thus,
people with this HLA may have a larger
fraction of CD8+ T cells that can cross-
react with point mutations of HIV epito-
pes that emerge during infection (113).
This may contribute to the ability of
people with this gene to be more likely
to control HIV infections (114).
Proposed General Model. Taking all the
available evidence together, we propose
the following model for TCR recognition
of pMHCs (Fig. 3). On encountering a
pMHC complex, a TCR scans the ligand
to see if a sufﬁcient number of moderate
interactions are established (bar code
model). Note that steric hindrance could
prevent scanning of the bar code. If
the bar code is recognized, the interac-
tion can persist to allow enough time
for possible modest induced ﬁt changes
in conformation to stabilize the in-
teraction further. Improved binding at-
tributable to variations in TCR ﬂexibility
may occur differently with various
TCR-pMHC pairs, depending on their
detailed chemical features. This general
model is also consistent with ﬁndings
for the LC13 TCR which, on recognizing
two very different peptides, induces
a similar peptide conformation in both.
The model we propose would suggest
that on recognition of the bar code, the
TCR
pMHC
TCR
pMHC
TCR
pMHC
Fig. 3. Bar code model for speciﬁcity of TCR–pMHC interactions. The thickness of the lines in the car-
toon is proportional to the strength of interactions between residues of the TCR CDR3 and those of the
counterparty (epitope). After scanning the epitope and formation of an encounter complex (if con-
ditions described in the text are met), modest changes in conformation of the TCR and, in some in-
stances, of the epitope may ensue and lead to improved ﬁt and strength of interactions.
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induced better ﬁt (and afﬁnity) in this
case was affected by peptide conforma-
tion changes.
Summing Up Abs and TCRs Compared. Ags
introduced by infection or vaccines usually
elicit production of complex polyclonal
mixtures of Abs and T cells. These can
appear to be highly speciﬁc because es-
sentially all individual components can
react with the introduced Ag (e.g., A),
whereas subsets that cross-react with
other Ags (e.g., X, Y, or Z) may be un-
detected if they constitute only small
fractions of the total (115). Only with the
advent of mAbs, foreshadowed by mye-
loma proteins, and T-cell clones that can
be perpetuated in culture or in TCR
transgenic mice has it become widely
appreciated that many Abs and TCRs
are able to recognize ligands speciﬁcally
and degenerately. Abs exercise this ability
primarily by conformational isomerism—
folding into various conformations that
bind different ligands and undergo fur-
ther conformational changes to enhance
shape and chemical complementarity to
the bound ligand (“induced ﬁt”). The
Abs initially elicited by Ags are diversiﬁed
by multiple mutations in Ab V domains in
Ag-activated B cells. Mutant B cells
that express higher afﬁnity Abs are se-
lectively stimulated by Ags to expand.
Depending on the Ag, selection can lead
to high-afﬁnity Abs whose binding sites
are relatively rigid and highly speciﬁc
or ﬂexible and multireactive, particu-
larly if they can engage in a form of
asymmetrical bivalent binding (heter-
oligation) to some pathogens, for
example, as suggested recently for
HIV-1 virions.
Unlike B cells, somatic hypermutation
does not occur in Ag-stimulated T cells.
The ability of their TCRs to recognize many
different MHC-bound peptides (epitopes),
and yet discriminate sharply among small
variants of them, may be inﬂuenced by the
way in which TCR sequences (e.g., in
CDR3) are stochastically selected during
T-cell development. As described, these
sequences may account for speciﬁc binding
to a peptide for a duration that is long
enough for further augmentation of binding
afﬁnity by relatively rigid and modest
conformational changes. Despite the ab-
sence of TCR hypermutation, the great
diversity of these receptors in highly
polyclonal populations of Ag-stimulated
T cells provides opportunities for Ags
to selectively promote the expansion of T
cells whose TCRs have higher afﬁnity
for the Ag (116) or for T cells with
enhanced responsiveness to an Ag
without detectable change in TCR afﬁn-
ity (117).
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